Table 2.
Subjects | Age | Amount and Duration of Supplementation | Form of Vitamin E Used | Effects on Immune Function | References |
---|---|---|---|---|---|
Young (n = 5) and senior athletes (n = 5) | 18–25, 35–57 | 4.6 ± 0.3 mg/100 mL of vitamin E-enriched beverage 5 days/week for 5 weeks | α-tocopherol acetate | ↑15LOX2, TNF-α expression | Capo et al. 2016 [20] |
Healthy women (n = 108) | 18–25 | 400 mg TRF/day for 56 days | d-α-tocotrienol | ↑IL-4 (TT vaccine), IFN-γ (ConA) | Mahalingam et al. 2011 [21] |
d-γ-tocotrienol | |||||
d-δ-tocotrienol | ↓IL-6 (LPS) | ||||
d-α-tocopherol | |||||
Healthy men and women (n = 19, 34) | 20–50 | 200 mg/day for 56 days | α-tocopherol | ↔IL-4, IFN-γ production (ConA) | Radhakrishnan et al. 2009 [22] |
Adult males and young boys (n = 18) | 25–30, 13–18 | 300 mg/day for 3 weeks | dl-α-tocopheryl acetate | ↓Lymphocyte proliferation (PHA) | Prasad 1980 [23] |
↔DTH | |||||
↓Bactericidal activity | |||||
Institutionalized adult males and females (n = 103) | 24–104 | 200, 400 mg/day for 6 months | α-tocopherol acetate | ↔Ab development to influenza virus | Harman and Miller 1986 [24] |
Healthy elderly males and females (n = 32) | ≥60 | 800 mg/day for 30 days | dl-α-tocopheryl acetate | ↑Lymphocyte proliferation (ConA) | Meydani et al. 1990 [25] |
↑DTH | |||||
↑IL-2 production (ConA) | |||||
↓PGE2 production (PHA) | |||||
Eldery males and females (n = 74) | ≥65 | 100 mg/day for 3 months | dl-α-tocopheryl acetate | ↔Lymphocyte proliferation (ConA, PHA) | De Waart et al. 1997 [26] |
↔IgG, IgA levels | |||||
Healthy elderly males and females (n = 88) | ≥65 | 60, 200, 800 mg/day for 235 days | dl-α-tocopherol | ↑DTH and antibody titer to hepatitis B with 200, 800 mg | Meydani et al. 1997 [27] |
Healthy elderly males and females (n = 161) | 65–80 | 50, 100 mg/day for 6 months | dl-α-tocopheryl acetate | ↑No. of positive DTH reaction with 100 mg | Pallast et al. 1999 [28] |
↑dDiameter of induration of DTH reaction in a subgroup supplemented with 100 mg | |||||
↔IL-2 production | |||||
↓IFN-γ production | |||||
Healthy young adults (n = 31) and premature infants (n = 10) | 24–31 | 600 mg/day for 3 months40 mg/kg body weight for 8–14 days | ↓Chemiluminescence | Okano et al. 1990 [29] | |
Cigarette smoker (n = 60) | 33 ± 4 | 900 IU/day for 6 weeks | ↓Chemiluminescence | Richards et al. 1990 [30] | |
Healthy males (n = 40) | 24–57 | 200 mg/day for 4 months | all-rac-α-tocopherol | Prevented fish-oil-induced suppression of ConA mitogenesis | Kramer et al. 1991 [31] |
Healthy elderly (n = 40) | >65 | 100, 200, or 400 mg/day for 3 months | dl-α-tocopherol | ↑DTH (maximal diameter) in 100, 200, 400 mg groups | Wu et al. 2006 [32] |
↑Lymphocyte proliferation (ConA) in 200 mg group | |||||
Sedentary young and elderly males (n = 21) | 22–29, 55–74 | 800 IU (727 mg)/day for 48 days | dl-α-tocopherol | ↓IL-6 secretion | Cannon et al. 1991 [33] |
↓Exercise-enhanced IL-1β secretion |
ConA, concanavalin A; DTH, delayed type hypersensitivity; IFN-γ, interferon-γ; 15LOX2, 15-lipoxygenase-2; PGE2, prostaglandin E2; PHA, phytohemagglutinin; TRF, tocotrienol-rich fraction; TT vaccine, tetanous toxoid vaccine.